adenosine monophosphate has been researched along with Diabetes Mellitus, Type 2 in 46 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (6.52) | 18.2507 |
| 2000's | 13 (28.26) | 29.6817 |
| 2010's | 13 (28.26) | 24.3611 |
| 2020's | 17 (36.96) | 2.80 |
| Authors | Studies |
|---|---|
| Brown, BS; Dang, Q; Erion, MD; Liu, Y; Reddy, MR; Robinson, ED; Rydzewski, RM; van Poelje, PD | 1 |
| Benardeau, A; Benz, J; Gubler, M; Haap, W; Hebeisen, P; Huber, W; Joseph, C; Kitas, E; Kuhn, B; Mohr, P; Paehler, A; Ruf, A; Sanchez, RA; Schott, B; Tozzo, E; Wessel, HP | 1 |
| Duan, Y; Gu, Z; Jiang, H; Li, J; Liu, H; Sun, H; Tong, J; Wang, J; Zhang, J; Zhou, S | 1 |
| Chen, X; Huang, YY; Li, J; Li, XK; Mao, F; Ni, SS; Ren, YL; Song, RR; Wan, J; Xu, YX; Zhang, C; Zhu, J | 1 |
| Cao, J; Chang, X; Gao, M; Jiang, C; Yin, Z; Zhang, D; Zhang, J; Zhao, Y; Zheng, R | 1 |
| Akalestou, E; Burade, V; Carrat, G; Jones, B; Leclerc, I; Manchanda, Y; Marchetti, P; Nguyen-Tu, MS; Piemonti, L; Ramchunder, Z; Rutter, GA; Thennati, R; Thorens, B; Tomas, A; Vilsboll, T | 1 |
| Altamirano, J; García, N; Garza-González, S; Nieblas, B; Solbes-Gochicoa, MM | 1 |
| Mathai, ML; McAinch, AJ; Shi, M; Su, XQ; Xu, G | 1 |
| Huang, M; Jia, S; Wang, P; Wei, J; Wei, Y | 1 |
| Anghel, R; Forsea, L; Gales, L; Georgescu, M; Mitrea, D; Mitrica, R; Serbanescu, L; Stanculescu, I; Stefanica, I; Trifanescu, O | 1 |
| Berger, AM; Goldner, W; Hammer, MJ; Klute, K; Langenfeld, SJ; Rasmussen Mandolfo, N; Shade, MY; Struwe, LA | 1 |
| Armstrong, DG; Chen, T; Deng, B; Deng, W; Duan, X; Ma, Y; Rui, S; Song, P | 1 |
| Kouzu, H; Kuno, A; Miura, T; Ogawa, T; Ohwada, W; Osanami, A; Sato, T; Shimizu, M; Tanno, M; Toda, Y; Yano, T | 1 |
| Cheng, J; Morisaki, H; Morisaki, T; Wang, Q; Xi, Y; Yang, H; Yu, W | 1 |
| Basta, G; Calafiore, R; Luca, G; Mazzieri, A | 1 |
| Packer, M | 1 |
| Azmy, V; Benson, J; Love, K; Steele, R | 1 |
| Hardie, DG; Russell, FM | 1 |
| Devi, S; Kar, N; Mohakud, S; Muthuvel, D | 1 |
| Ishikawa, K; Kumagai, J; Maezawa, Y; Matumoto, A; Ochiai, H; Ohno, T; Ono, H; Takeda, K; Yokoh, H; Yokote, K | 1 |
| Chang, L; Ding, Z; Hu, L; Kunapuli, SP; Luo, X; Qi, Z; Wang, Y; Yan, H; Yan, Y; Ye, H; Zhai, L; Zhang, S; Zhang, Y | 1 |
| Timson, DJ | 1 |
| Sieck, G | 1 |
| Cleator, JH; Colowick, NE; Duvernay, MT; Hamm, HE; Harrell, FE; Holinstat, M; Hudson, WJ; Song, Y | 1 |
| Arumugam, R; Dai, X; Ferdaoussi, M; Gooding, JR; Jensen, MV; Lu, D; MacDonald, PE; Newgard, CB; Wenner, BR | 1 |
| Bolek, T; Fedor, M; Galajda, P; Kovář, F; Kubisz, P; Mokáň, M; Samoš, M | 1 |
| Gugliucci, A | 1 |
| Fujisawa, K; Hiemori, M; Iwabuchi, H; Jozuka, M; Kimoto, M; Kimura, R; Maruta, H; Saito, T; Takahashi, Y; Tsuji, H; Yamashita, H; Yamato, M | 1 |
| Beck-Nielsen, H; Birk, JB; Hansen, BF; Højlund, K; Klein, DK; Levin, K; Nielsen, JN; Rose, AJ; Wojtaszewski, JF | 1 |
| Dang, Q; Dare, J; Erion, MD; Gibson, T; Kasibhatla, SR; Liu, Y; Potter, SC; Reddy, KR; Scarlato, GR; Taplin, F; van Poelje, PD; Xiao, W | 1 |
| Erion, MD; Reddy, MR; Singh, UC | 1 |
| Hua, Z; Wang, S; Wang, Z; Zhang, J; Zhang, Y; Zhao, M; Zhao, Y | 1 |
| Bie, JB; Li, ZM; Song, HR; Xu, BL | 1 |
| Ishisaki, A; Kitajima, Y; Kozawa, O; Matsuno, H; Tokuda, H; Zhou, Y | 1 |
| Dang, Q; Erion, MD; Jiang, T; Kasibhatla, SR; Lipscomb, WN; Potter, SC; Reddy, KR; Reddy, MR; van Poelje, PD | 1 |
| Brachvogel, V; Burger, HJ; Defossa, E; Herling, AW; Kadereit, D; Klabunde, T; Kosmopoulou, MN; Oikonomakos, NG; Sarubbi, E; Schmoll, D; Schönafinger, K; von Roedern, E; Wendt, KU | 1 |
| Long, YC; Zierath, JR | 1 |
| Andreelli, F; Beauloye, C; Bertrand, L; Foretz, M; Guigas, B; Horman, S; Taleux, N; Viollet, B | 1 |
| Bakker, SJ; Ciapaite, J; Diamant, M; Heine, RJ; Krab, K; van Eikenhorst, G; Westerhoff, HV | 1 |
| Gao, Z; Liu, D; Liu, Z; Ye, J; Yin, J | 1 |
| Langkopf, E; Moreth, W; Pautsch, A; Stadler, N; Streicher, R; Wissdorf, O | 1 |
| Cao, PR; Gu, M; Li, J; Li, JY; Nan, FJ; Pang, T; Qiu, BY; Shao, W; Su, MB; Yu, LF; Zhang, ZS | 1 |
| Polonsky, KS; Pugh, W; Tang, J; Zhang, H | 1 |
| Ferreira, FM; Palmeira, CM; Santos, MS; Seiça, R | 1 |
| De Sole, P; Ghirlanda, G; Giardina, B; Marra, G; Persichilli, S; Pitocco, D; Zappacosta, B | 1 |
| Winder, WW | 1 |
10 review(s) available for adenosine monophosphate and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
Is metformin a possible treatment for diabetic neuropathy?
Topics: Adenosine Monophosphate; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Humans; Hypoglycemic Agents; Metformin; Neuroprotective Agents; Pain; Protein Kinases; Vitamin B 12 | 2022 |
Antidiabetics, Anthelmintics, Statins, and Beta-Blockers as Co-Adjuvant Drugs in Cancer Therapy.
Topics: Adenosine Monophosphate; Adrenergic beta-Antagonists; Anthelmintics; Anti-Bacterial Agents; Antihypertensive Agents; Antimalarials; Antineoplastic Agents; Atorvastatin; Breast Neoplasms; Cholesterol; Diabetes Mellitus, Type 2; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Male; Mebendazole; Metformin; Mevalonic Acid; Propranolol; Protein Kinases; Proto-Oncogene Proteins B-raf; Receptors, Adrenergic, beta-2; Tyrosine | 2022 |
GLP-1 RAs and SGLT2i: two antidiabetic agents associated with immune and inflammation modulatory properties through the common AMPK pathway.
Topics: Adenosine Monophosphate; AMP-Activated Protein Kinases; Diabetes Mellitus, Type 2; Glucagon-Like Peptide 1; Glucose; Humans; Hypoglycemic Agents | 2023 |
Interplay of adenosine monophosphate-activated protein kinase/sirtuin-1 activation and sodium influx inhibition mediates the renal benefits of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes: A novel conceptual framework.
Topics: Adenosine Monophosphate; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Glucose; Humans; Kidney; Pharmaceutical Preparations; Protein Kinases; Sirtuin 1; Sodium; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2020 |
AMP-Activated Protein Kinase: Do We Need Activators or Inhibitors to Treat or Prevent Cancer?
Topics: Adenosine Monophosphate; Adenosine Triphosphate; AMP-Activated Protein Kinases; Animals; Calcium-Calmodulin-Dependent Protein Kinase Kinase; Diabetes Mellitus, Type 2; DNA Damage; Energy Metabolism; Humans; Neoplasms; Phosphorylation; Protein Kinase Inhibitors; Signal Transduction; Tumor Suppressor Proteins | 2020 |
Physiology in perspective: the burden of obesity.
Topics: Adenosine Monophosphate; Cost of Illness; Diabetes Mellitus, Type 2; Humans; Obesity; Sex Characteristics; Social Support | 2014 |
Type 2 Diabetes and ADP Receptor Blocker Therapy.
Topics: Adenosine; Adenosine Monophosphate; Blood Platelets; Cardiovascular Diseases; Clopidogrel; Diabetes Mellitus, Type 2; Drug Resistance; Humans; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Risk Factors; Ticagrelor; Ticlopidine; Treatment Outcome | 2016 |
[Recent advance in the discovery of allosteric inhibitors binding to the AMP site of fructose-1,6-bisphosphatase].
Topics: Adenosine Monophosphate; Allosteric Site; Animals; Binding Sites; Blood Glucose; Diabetes Mellitus, Type 2; Enzyme Inhibitors; Fructose-Bisphosphatase; Fructosediphosphates; Fructosephosphates; Humans | 2011 |
[Regulation of energy metabolism by AMPK: a novel therapeutic approach for the treatment of metabolic and cardiovascular diseases].
Topics: Adenosine Monophosphate; Adenosine Triphosphate; Adipogenesis; Allosteric Regulation; AMP-Activated Protein Kinases; Animals; Cardiovascular Diseases; Cholesterol; Diabetes Mellitus, Type 2; Drug Design; Energy Intake; Energy Metabolism; Enzyme Activation; Fatty Acids; Glucose; Homeostasis; Humans; Hypothalamus; Lipogenesis; Mammals; Metformin; Models, Biological; Multienzyme Complexes; Myocardium; Obesity; Phosphorylation; Protein Processing, Post-Translational; Protein Serine-Threonine Kinases; Protein Structure, Tertiary; Protein Subunits; Rosiglitazone; Thiazolidinediones | 2006 |
AMP-activated protein kinase: possible target for treatment of type 2 diabetes.
Topics: Adenosine Monophosphate; Aminoimidazole Carboxamide; AMP-Activated Protein Kinases; Animals; Diabetes Mellitus, Type 2; Enzyme Activation; Glucose Transporter Type 4; Humans; Insulin; Monosaccharide Transport Proteins; Multienzyme Complexes; Muscle Contraction; Muscle Proteins; Muscle, Skeletal; Protein Serine-Threonine Kinases; Rats; Ribonucleotides | 2000 |
36 other study(ies) available for adenosine monophosphate and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
Fructose-1,6-bisphosphatase inhibitors. 1. Purine phosphonic acids as novel AMP mimics.
Topics: Adenosine Monophosphate; Administration, Oral; Animals; Biological Availability; Biomimetics; Diabetes Mellitus, Type 2; Drug Design; Enzyme Inhibitors; Fructose-Bisphosphatase; Glucose; Humans; Inhibitory Concentration 50; Liver; Organophosphonates; Purines; Rats; Rats, Sprague-Dawley; Structure-Activity Relationship; Substrate Specificity | 2009 |
Sulfonylureido thiazoles as fructose-1,6-bisphosphatase inhibitors for the treatment of type-2 diabetes.
Topics: Animals; Binding Sites; Crystallography, X-Ray; Diabetes Mellitus, Type 2; Disease Models, Animal; Fructose-Bisphosphatase; High-Throughput Screening Assays; Humans; Hypoglycemic Agents; Mice; Structure-Activity Relationship; Sulfonylurea Compounds; Thiazoles | 2010 |
Design, synthesis and biological evaluation of 4,7,12,12a-tetrahydro-5H-thieno[3',2':3,4]pyrido[1,2-b]isoquinolines as novel adenosine 5'-monophosphate-activated protein kinase (AMPK) indirect activators for the treatment of type 2 diabetes.
Topics: AMP-Activated Protein Kinases; Animals; Carbon-13 Magnetic Resonance Spectroscopy; Cell Line; Diabetes Mellitus, Type 2; Drug Design; Enzyme Activators; Hypoglycemic Agents; Isoquinolines; Mice; Proton Magnetic Resonance Spectroscopy; Rats; Spectrometry, Mass, Electrospray Ionization; Structure-Activity Relationship | 2017 |
Development of disulfide-derived fructose-1,6-bisphosphatase (FBPase) covalent inhibitors for the treatment of type 2 diabetes.
Topics: Animals; Blood Glucose; Cysteine; Diabetes Mellitus, Type 2; Disulfides; Enzyme Inhibitors; Fructose-Bisphosphatase; Male; Mice; Structure-Activity Relationship | 2020 |
Cyclocarya paliurus triterpenoids suppress hepatic gluconeogenesis via AMPK-mediated cAMP/PKA/CREB pathway.
Topics: Adenosine Monophosphate; AMP-Activated Protein Kinases; Animals; Cyclic AMP; Cyclic AMP-Dependent Protein Kinases; Diabetes Mellitus, Type 2; Glucagon; Gluconeogenesis; Glucose; Juglandaceae; Liver; Mice; RNA, Messenger; Triterpenes | 2022 |
In vivo and in vitro characterization of GL0034, a novel long-acting glucagon-like peptide-1 receptor agonist.
Topics: Adenosine Monophosphate; Animals; beta-Arrestins; Blood Glucose; Cyclic AMP; Diabetes Mellitus, Type 2; Glucagon-Like Peptide-1 Receptor; HEK293 Cells; Humans; Hypoglycemic Agents; Insulins; Ligands; Mice; Weight Loss | 2022 |
Intermittent Fasting as Possible Treatment for Heart Failure.
Topics: Adenosine Monophosphate; AMP-Activated Protein Kinases; Diabetes Mellitus, Type 2; Fasting; Heart Failure; Humans; Ketone Bodies; NF-E2-Related Factor 2; Sirtuins | 2022 |
The effect of dietary supplementation with blueberry, cyanidin-3-O-β-glucoside, yoghurt and its peptides on gene expression associated with glucose metabolism in skeletal muscle obtained from a high-fat-high-carbohydrate diet induced obesity model.
Topics: Adenosine Monophosphate; AMP-Activated Protein Kinases; Animals; Anthocyanins; Blueberry Plants; Diabetes Mellitus, Type 2; Diet, High-Fat; Dietary Supplements; Forkhead Box Protein O1; Gene Expression; Glucose; Glucose Transport Proteins, Facilitative; Insulin Receptor Substrate Proteins; Mice; Mice, Obese; Muscle, Skeletal; Obesity; Phosphatidylinositol 3-Kinases; Phosphatidylinositols; Receptors, Angiotensin; RNA, Messenger; Yogurt | 2022 |
Glycemic Variability in Patients With Stage II-III Colon Cancer Treated With Surgery and Adjuvant Chemotherapy.
Topics: Adenosine Monophosphate; Blood Glucose; Chemotherapy, Adjuvant; Colonic Neoplasms; Diabetes Mellitus, Type 2; Humans; Hyperglycemia; Retrospective Studies | 2022 |
Canagliflozin promotes osteoblastic MC3T3-E1 differentiation
Topics: Adenosine Monophosphate; AMP-Activated Protein Kinases; Animals; Bone Diseases, Metabolic; Canagliflozin; Core Binding Factor Alpha 1 Subunit; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Glucose; Mice | 2022 |
Adenosine monophosphate deaminase in the endoplasmic reticulum-mitochondria interface promotes mitochondrial Ca
Topics: Adenosine Monophosphate; Animals; Diabetes Mellitus, Type 2; Endoplasmic Reticulum; Humans; Mitochondria; Rats; Rats, Inbred OLETF; Rats, Long-Evans | 2023 |
AMPD2 plays important roles in regulating hepatic glucose and lipid metabolism.
Topics: Adenosine Monophosphate; AMP Deaminase; Animals; Cholesterol; Diabetes Mellitus, Type 2; Diet, High-Fat; Glucose; Insulin Resistance; Lipid Metabolism; Liver; Mice; Mice, Inbred C57BL; Obesity | 2023 |
Idiopathic nonhistaminergic acquired angioedema in a patient with coronavirus disease 2019.
Topics: Adenosine Monophosphate; Adult; Alanine; Ampicillin; Angioedema; Betacoronavirus; Coronavirus Infections; COVID-19; Diabetes Mellitus, Type 2; Female; Humans; Hydroxychloroquine; Hyperlipidemias; Intubation, Intratracheal; Obesity; Pandemics; Pneumonia, Viral; Respiration, Artificial; Respiratory Insufficiency; SARS-CoV-2; Treatment Outcome | 2020 |
Deep vein thrombosis with pulmonary thromboembolism in a case of severe COVID-19 pneumonia.
Topics: Adenosine Monophosphate; Alanine; Anti-Bacterial Agents; Anticoagulants; Antiparasitic Agents; Antiviral Agents; Computed Tomography Angiography; COVID-19; COVID-19 Drug Treatment; Diabetes Mellitus, Type 2; Doxycycline; Femoral Vein; Fibrin Fibrinogen Degradation Products; Glucocorticoids; Heparin, Low-Molecular-Weight; Humans; Ivermectin; Male; Methylprednisolone; Middle Aged; Oxygen Inhalation Therapy; Popliteal Vein; Pulmonary Embolism; SARS-CoV-2; Tomography, X-Ray Computed; Ultrasonography, Doppler, Color; Venous Thrombosis | 2021 |
Central administration of sodium-glucose cotransporter-2 inhibitors increases food intake involving adenosine monophosphate-activated protein kinase phosphorylation in the lateral hypothalamus in healthy rats.
Topics: Adenosine Monophosphate; AMP-Activated Protein Kinases; Animals; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Eating; Glucose; Glucosides; Hypothalamic Area, Lateral; Phosphorylation; Rats; Sodium; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2021 |
Platelets Express Activated P2Y
Topics: Adenosine Monophosphate; Animals; Blood Platelets; Cell Adhesion Molecules; Cell Line; Chlorides; Cyclic AMP; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Disease Models, Animal; Drug Inverse Agonism; Ferric Compounds; Fibrinolytic Agents; Humans; Male; Microfilament Proteins; NF-kappa B; Phosphoproteins; Platelet Aggregation; Platelet Aggregation Inhibitors; Rats; Rats, Wistar; Reactive Oxygen Species; Receptors, Purinergic P2Y12; Thrombosis | 2017 |
Fructose 1,6-
Topics: Adenosine Monophosphate; Animals; Diabetes Mellitus, Type 2; Fructose; Fructose-Bisphosphatase; Mutation | 2019 |
Racial differences in resistance to P2Y12 receptor antagonists in type 2 diabetic subjects.
Topics: Adenosine Monophosphate; Adult; Black or African American; Blood Platelets; Diabetes Mellitus, Type 2; Drug Resistance; Female; Humans; Male; Purinergic P2Y Receptor Antagonists; White People | 2014 |
Adenylosuccinate Is an Insulin Secretagogue Derived from Glucose-Induced Purine Metabolism.
Topics: Adenosine Monophosphate; Adenylosuccinate Lyase; Adenylosuccinate Synthase; Animals; Cell Line, Tumor; Cysteine Endopeptidases; Diabetes Mellitus, Type 2; Endopeptidases; Enzyme Inhibitors; Exocytosis; Gene Expression Regulation; Glucose; Guanine; Humans; Inosine Monophosphate; Insulin; Insulin Secretion; Insulin-Secreting Cells; Metabolome; Mycophenolic Acid; Patch-Clamp Techniques; Primary Cell Culture; Rats; Rats, Sprague-Dawley; Signal Transduction | 2015 |
Fructose surges damage hepatic adenosyl-monophosphate-dependent kinase and lead to increased lipogenesis and hepatic insulin resistance.
Topics: Adenosine Monophosphate; Adenylate Kinase; Allosteric Site; AMP-Activated Protein Kinases; Animals; Binding Sites; Diabetes Mellitus, Type 2; Fatty Liver; Fructose; Gene Silencing; Glucose; Humans; Insulin Resistance; Lipogenesis; Liver; Metabolic Syndrome; Models, Theoretical; Phosphorylation; Portal Vein; Pyruvaldehyde; Stochastic Processes; Uric Acid | 2016 |
Effects of acetate on lipid metabolism in muscles and adipose tissues of type 2 diabetic Otsuka Long-Evans Tokushima Fatty (OLETF) rats.
Topics: Abdominal Muscles; Acetates; Adenosine Monophosphate; Adenosine Triphosphate; Adipocytes, Brown; Adipocytes, White; Adipose Tissue; AMP-Activated Protein Kinases; Animals; Diabetes Mellitus, Type 2; Energy Metabolism; Gene Expression Regulation; Glucose Transporter Type 4; Lipid Metabolism; Male; Muscle, Skeletal; Myoglobin; Oxygen; Phosphorylation; Rats; Rats, Inbred OLETF; RNA, Messenger | 2009 |
Dysregulation of glycogen synthase COOH- and NH2-terminal phosphorylation by insulin in obesity and type 2 diabetes mellitus.
Topics: Adenosine Monophosphate; Blotting, Western; Calcium; Diabetes Mellitus, Type 2; Female; Glucose; Glucose Tolerance Test; Glycogen Synthase; Homeostasis; Humans; Insulin; Kinetics; Male; Middle Aged; Muscle, Skeletal; Obesity; Phosphoric Monoester Hydrolases; Phosphorylation; Reference Values; Signal Transduction | 2009 |
Fructose-1,6-bisphosphatase Inhibitors. 2. Design, synthesis, and structure-activity relationship of a series of phosphonic acid containing benzimidazoles that function as 5'-adenosinemonophosphate (AMP) mimics.
Topics: Adenosine Monophosphate; Animals; Benzimidazoles; Diabetes Mellitus, Type 2; Disease Models, Animal; Drug Design; Enzyme Inhibitors; Fructose-Bisphosphatase; Humans; Liver; Molecular Structure; Organophosphonates; Rats; Rats, Zucker; Stereoisomerism; Structure-Activity Relationship | 2010 |
Use of a QM/MM-based FEP method to evaluate the anomalous hydration behavior of simple alkyl amines and amides: application to the design of FBPase inhibitors for the treatment of type-2 diabetes.
Topics: Acetamides; Adenosine Monophosphate; Computer Simulation; Diabetes Mellitus, Type 2; Enzyme Inhibitors; Fructose-Bisphosphatase; Humans; Inosine Monophosphate; Methylamines; Molecular Dynamics Simulation; Quantum Theory; Thermodynamics | 2011 |
The plasma 5'-AMP acts as a potential upstream regulator of hyperglycemia in type 2 diabetic mice.
Topics: Adenosine; Adenosine Monophosphate; Animals; Cells, Cultured; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Female; Glycogenolysis; Human Umbilical Vein Endothelial Cells; Humans; Hyperglycemia; Insulin Resistance; Liver; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Mice, Mutant Strains; Muscle, Skeletal; Necrosis; Protein Isoforms; Receptors, Purinergic P1 | 2012 |
P2Y12 receptors play a significant role in the development of platelet microaggregation in patients with diabetes.
Topics: Adenosine Diphosphate; Adenosine Monophosphate; Aged; Diabetes Mellitus, Type 2; Female; Humans; Male; Membrane Proteins; Middle Aged; Piperazines; Piperidines; Platelet Aggregation; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2; Receptors, Purinergic P2Y12; Reference Values | 2005 |
MB06322 (CS-917): A potent and selective inhibitor of fructose 1,6-bisphosphatase for controlling gluconeogenesis in type 2 diabetes.
Topics: Adenosine Monophosphate; Alanine; Analysis of Variance; Animals; Carbon Radioisotopes; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Design; Fructose-Bisphosphatase; Gluconeogenesis; Humans; Liver; Male; Molecular Mimicry; Organophosphonates; Organophosphorus Compounds; Rats; Rats, Sprague-Dawley; Rats, Zucker; Spectrophotometry; Thiazoles | 2005 |
Acyl ureas as human liver glycogen phosphorylase inhibitors for the treatment of type 2 diabetes.
Topics: Adenosine Monophosphate; Allosteric Site; Animals; Binding Sites; Crystallography, X-Ray; Diabetes Mellitus, Type 2; Glycogen Phosphorylase, Liver Form; Glycogen Phosphorylase, Muscle Form; Hepatocytes; Humans; In Vitro Techniques; Models, Molecular; Quantitative Structure-Activity Relationship; Rabbits; Rats; Urea | 2005 |
Fine-tuning insulin and nitric oxide signalling by turning up the AMPs: new insights into AMP-activated protein kinase signalling.
Topics: Adenosine Monophosphate; Aminoimidazole Carboxamide; AMP-Activated Protein Kinases; Animals; Diabetes Mellitus, Type 2; Enzyme Activation; Glucose; Insulin; Male; Multienzyme Complexes; Myocardium; Nitric Oxide; Nitric Oxide Donors; Nitroprusside; Phosphatidylinositol 3-Kinases; Phosphorylation; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins c-akt; Rats; Rats, Sprague-Dawley; Ribonucleotides; Signal Transduction | 2005 |
Metabolic control of mitochondrial properties by adenine nucleotide translocator determines palmitoyl-CoA effects. Implications for a mechanism linking obesity and type 2 diabetes.
Topics: Adenosine Diphosphate; Adenosine Monophosphate; Adenosine Triphosphate; Animals; Diabetes Mellitus, Type 2; Hydrogen Peroxide; Male; Mitochondria, Liver; Mitochondrial ADP, ATP Translocases; Models, Biological; Obesity; Oxidation-Reduction; Palmitoyl Coenzyme A; Rats; Reactive Oxygen Species | 2006 |
Berberine improves glucose metabolism through induction of glycolysis.
Topics: 3T3-L1 Cells; Adenosine Monophosphate; Adenosine Triphosphate; Adipocytes; AMP-Activated Protein Kinases; Animals; Berberine; Deoxyglucose; Diabetes Mellitus, Type 2; Drugs, Chinese Herbal; Glucose; Glucose Intolerance; Glycolysis; Insulin Resistance; Lactic Acid; Male; Mice; Mitochondria; Multienzyme Complexes; Obesity; Oxygen Consumption; Phosphorylation; Protein Serine-Threonine Kinases; Rats; Rats, Wistar | 2008 |
Molecular recognition of the protein phosphatase 1 glycogen targeting subunit by glycogen phosphorylase.
Topics: Adenosine Monophosphate; Amino Acid Motifs; Diabetes Mellitus, Type 2; Dimerization; Glycogen Phosphorylase, Liver Form; Humans; Hydrophobic and Hydrophilic Interactions; Peptides; Protein Binding; Protein Phosphatase 1; Protein Structure, Quaternary; Protein Subunits | 2008 |
Small molecule antagonizes autoinhibition and activates AMP-activated protein kinase in cells.
Topics: Acetyl-CoA Carboxylase; Adenosine Monophosphate; Adenosine Triphosphate; AMP-Activated Protein Kinase Kinases; AMP-Activated Protein Kinases; Benzimidazoles; Diabetes Mellitus, Type 2; Energy Metabolism; Enzyme Activation; Enzyme Activators; HeLa Cells; Humans; Multienzyme Complexes; Myoblasts; Naphthalimides; Obesity; Phosphorylation; Protein Serine-Threonine Kinases; Protein Structure, Quaternary; Pyrazoles; Pyrimidines; Time Factors | 2008 |
Preservation of insulin secretory responses to P2 purinoceptor agonists in Zucker diabetic fatty rats.
Topics: Adenosine; Adenosine Diphosphate; Adenosine Monophosphate; Adenosine Triphosphate; Analysis of Variance; Animals; Blood Glucose; Body Weight; Calcium; Diabetes Mellitus; Diabetes Mellitus, Type 2; In Vitro Techniques; Insulin; Insulin Secretion; Islets of Langerhans; Kinetics; Male; Obesity; Perfusion; Potassium Chloride; Purinergic P2 Receptor Agonists; Rats; Rats, Wistar; Rats, Zucker; Reference Values; Thionucleotides; Time Factors | 1996 |
Age-related alterations in liver mitochondrial bioenergetics of diabetic Goto-Kakizaki rats.
Topics: Adenosine Diphosphate; Adenosine Monophosphate; Adenosine Triphosphate; Aging; Analysis of Variance; Animals; Blood Glucose; Diabetes Mellitus, Type 2; Energy Metabolism; Liver; Male; Mitochondria, Liver; Oxygen Consumption; Rats; Rats, Mutant Strains; Rats, Wistar | 1999 |
Purine metabolites and malondialdehyde in platelets of diabetic patients.
Topics: Adenosine; Adenosine Monophosphate; Adolescent; Adult; Aged; Blood Platelets; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Female; Guanine Nucleotides; Humans; Male; Malondialdehyde; Middle Aged; Purines; Reference Values | 1999 |